Aurora Cannabis Inc. (NASDAQ:ACB) Q2 2025 Earnings Conference Call November 6, 2024 8:00 AM ET
Company Participants
Kevin Niland - Director, Strategic Finance and IR
Miguel Martin - CEO
Simona King - CFO
Conference Call Participants
Frederico Gomes - ATB Capital Markets
Pablo Zuanic - Zuanic & Associates
Operator
Greetings and welcome to the Aurora Cannabis Inc. Second Quarter 2025 Results Conference Call. all participants will be in a listen-only mode and a question-and-answer session will follow the formal presentation. This conference call is being recorded today, Wednesday, November 6, 2024. I would now like to turn the conference over to your host, Kevin Niland, Director of Strategic Finance and Investor Relations. Please go ahead.
Kevin Niland
Hello, everyone and thank you for joining us. On the line with me are Miguel Martin, Executive Chairman and CEO; and Simona King, CFO. This morning, we filed our financials for the second quarter 2025 period ending September 30, 2024. We issued a news releases containing our quarterly results. Our financial statements, MD&A with news release are available on our IR website and can also be accessed via SEDAR+ and EDGAR. For today's conference call, listeners are reminded that certain matters that constitute forward-looking statements are subject to risks and uncertainties related to our future financial or business performance. Actual results could differ materially from those anticipated in these forward-looking statements. The risk factors that may affect actual results are detailed in our annual information form and other periodic filings and registration statements. These documents may similarly be access via SEDAR+ and EDGAR. Following prepared remarks by Miguel and Simona, we will conduct a question-and-answer session with our covering analysts. With that, I'll turn the call over to Miguel. Please go ahead.
Miguel Martin
Thank you Kevin. We had a strong Q2 and look forward to building on that moment. Our prime positioning as a leader within nationally legal cannabis markets has set the foundation for topline growth and higher profitability as we further penetrated existing markets such as Canada, Europe, and Australia. And entered new ones as they opened. In doing so we will place more distance between ourselves and our peers by leading into what sets Aurora apart including first, capitalizing on rapidly evolving global medical cannabis opportunities that backed by our EU GMP manufacturing facilities, unparalleled scientific knowledge, genetics, and regulatory expertise. Second, leveraging our continued focus on operational excellence so that we can maintain our enviable margin profile and medical cannabis the highest margin industry segment. And third, maintaining and solidifying our balance sheet to maximize flexibility while also continuously focusing on profitable growth as evidenced by our record adjusted EBITDA.